gabapentin has been researched along with ambroxol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arndt, K; Gaida, W; Klinder, K; Weiser, T | 1 |
| Kern, KU; Weiser, T | 1 |
2 other study(ies) available for gabapentin and ambroxol
| Article | Year |
|---|---|
Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain.
Topics: Ambroxol; Amines; Analgesics; Animals; Behavior, Animal; Constriction, Pathologic; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Formaldehyde; Gabapentin; gamma-Aminobutyric Acid; Inflammation; Ligation; Male; NAV1.8 Voltage-Gated Sodium Channel; Nerve Tissue Proteins; Pain; Pain Measurement; Rats; Rats, Wistar; Sciatic Neuropathy; Sodium Channel Blockers; Sodium Channels | 2005 |
Topical ambroxol for the treatment of neuropathic pain. An initial clinical observation.
Topics: Administration, Topical; Adult; Aged; Ambroxol; Amines; Anesthetics, Local; Cyclohexanecarboxylic Acids; Drug Administration Schedule; Drug Therapy, Combination; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Neuralgia; Pain Measurement; Pain, Postoperative; Patient Satisfaction; Retrospective Studies | 2015 |